SCHEMBL6735303

SCHEMBL6735303

Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1nnnc1-c1ccc(Br)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.42
KCNA3 P22001 2/20 0.42
LMNA P02545 5/20 0.41
TSHR P16473 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
AGTR1 P30556 2/20 0.41
HTT P42858 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 2/20 0.41
SLC22A1 O15245 1/20 0.41
NR1I2 O75469 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
TRPM2 O94759 1/20 0.41
ABCB11 O95342 1/20 0.41
EGFR P00533 1/20 0.41
CA2 P00918 1/20 0.41
NR3C1 P04150 1/20 0.41
ERBB2 P04626 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734765 0.87 KCNN4 (0.40) KCNN4KCNA3LMNATSHRKMT2A
SCHEMBL6735541 0.84 KCNN4 (0.41) KCNN4KCNA3LMNATSHRKMT2A
SCHEMBL23357842 0.77 ALDH1A1 (0.42) LMNATSHRAGTR1HTTL3MBTL1
SCHEMBL976147 0.76 LMNA (0.47) LMNATSHRKMT2AAGTR1HTT
SCHEMBL6732605 0.75 SLC6A2 (0.42) KCNN4KCNA3LMNATSHRKMT2A
SCHEMBL9235857 0.74 MEN1 (0.42) LMNATSHRKMT2AMEN1AGTR1
SCHEMBL9025603 0.73 MEN1 (0.41) LMNATSHRKMT2AMEN1AGTR1
SCHEMBL3880938 0.73 ALDH1A1 (0.49) KCNN4KCNA3LMNAAGTR1SLC6A2
SCHEMBL7196989 0.72 AGTR1 (0.41) LMNATSHRAGTR1HTTL3MBTL1
SCHEMBL2794707 0.71 AGTR1 (0.44) KCNN4KCNA3LMNATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127507-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-07-01 US disclosed
US-20040122026-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. 2004-06-24 US disclosed
US-20030225288-A1 Imidazolidine compounds MILLENNIUM PHARMACEUTICALS, INC. 2003-12-04 US disclosed
WO-2003087063-A1 IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127507-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 KCNN4 1064/4885KCNA3 3397/4885LMNA 4169/4885
US-20030225288-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 KCNN4 1064/4885KCNA3 3397/4885LMNA 4169/4885
US-20040122026-A1 Imidazolidine compounds IRAK1, IRAK4, IRAK2 KCNN4 1064/4885KCNA3 3397/4885LMNA 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.